Evidence map›Paper›PMID 27214236›Full record

ArticlePLoS neglected tropical diseases2016

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.

Fiona R Strouts, Stephen J Popper, Charalambos D Partidos, Dan T Stinchcomb, Jorge E Osorio, David A Relman

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Fiona R StroutsDepartment of Microbiology and Immunology, Stanford University, Stanford, California, United States of America.
Stephen J PopperDepartment of Microbiology and Immunology, Stanford University, Stanford, California, United States of America.
Charalambos D PartidosTakeda Vaccines, Inc., Deerfield, Illinois, United States of America.
Dan T StinchcombTakeda Vaccines, Inc., Deerfield, Illinois, United States of America.
Jorge E OsorioTakeda Vaccines, Inc., Deerfield, Illinois, United States of America.
David A RelmanDepartment of Microbiology and Immunology, Stanford University, Stanford, California, United States of America.
Deerfield (United States) · USStanford University · USTakeda (United States) · USVA Palo Alto Health Care System · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
Translational CoreU19AI109761 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARIC, RALPH S · 2014 to 2018
$32.6M
EXTRAMURAL RES FACIL CONST: REPRODUCTIVE, GROWTH &DVMT, MENOPAUSEC06RR020141 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2004 to 2004
$3.6M
EXTRAMURAL REGIONAL FACILITIES CONSTRUCTIONC06RR015459 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2000 to 2000
$1.9M
NCRR NIH HHS C06 RR015459NCRR NIH HHS C06 RR020141NIAID NIH HHS HHSN272201000034CNIAID NIH HHS U19 AI109761NIAID NIH HHS U54 AI065359NIH HHS P51 OD011106
6 · The paper itself

Abstract

backgroundThe development of a vaccine against dengue faces unique challenges, including the complexity of the immune responses to the four antigenically distinct serotypes. Genome-wide transcriptional profiling provides insight into the pathways and molecular features that underlie responses to immune system stimulation, and may facilitate predictions of immune protection. METHODOLOGY/PRINCIPAL

findingsIn this study, we measured early transcriptional responses in the peripheral blood of cynomolgus macaques following vaccination with a live, attenuated tetravalent dengue vaccine candidate, TDV, which is based on a DENV-2 backbone. Different doses and routes of vaccine administration were used, and viral load and neutralizing antibody titers were measured at different time-points following vaccination. All 30 vaccinated animals developed a neutralizing antibody response to each of the four dengue serotypes, and only 3 of these animals had detectable serum viral RNA after challenge with wild-type dengue virus (DENV), suggesting protection of vaccinated animals to DENV infection. The vaccine induced statistically significant changes in 595 gene transcripts on days 1, 3, 5 and 7 as compared with baseline and placebo-treated animals. Genes involved in the type I interferon (IFN) response, including IFI44, DDX58, MX1 and OASL, exhibited the highest fold-change in transcript abundance, and this response was strongest following double dose and subcutaneous (versus intradermal) vaccine administration. In addition, modules of genes involved in antigen presentation, dendritic cell activation, and T cell activation and signaling were enriched following vaccination. Increased abundance of gene transcripts related to T cell activation on day 5, and the type I IFN response on day 7, were significantly correlated with the development of high neutralizing antibody titers on day 30. CONCLUSIONS/SIGNIFICANCE: These results suggest that early transcriptional responses may be predictive of development of adaptive immunity to TDV vaccination in cynomolgus macaques, and will inform studies of human responses to dengue vaccines.

Indexed as

Gene Expression ProfilingAdaptive ImmunityAnimalsAntibodies, NeutralizingAntibodies, ViralAntigen PresentationDengueDengue VaccinesDengue VirusHumansInterferon Type IPrimatesSerogroupSignal TransductionVaccinationVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralDengue VaccinesInterferon Type IVaccines, Attenuated

Identifiers

PMID27214236
PMCPMC4877054
OpenAlexW2400637246

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.